Wedbush Securities’s Carisma Therapeutics CARM Stock Holding History

Wedbush Securities’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-811	Closed	-$13K	–	830
2017 Q4	$13K	Buy	+811	New	+$15.1K	﹤0.01%	848

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wedbush Securities's CARM Position: Q1 2018 in Review

Wedbush Securities sold out of Carisma Therapeutics (CARM) in Q1 2018, closing a stake of 811 shares — an estimated $13K sold.

Wedbush Securities first reported a position in CARM in Q4 2017 and held it in 1 quarter. The position peaked at $13K in Q4 2017. 27 funds tracked by Wall St. Rank hold CARM as of Q1 2018.

Wedbush Securities reported no remaining Carisma Therapeutics position as of Q1 2018 after selling out during the quarter.
Wedbush Securities sold 811 Carisma Therapeutics shares in Q1 2018, an estimated $13K.
Wedbush Securities first reported a position in Carisma Therapeutics in Q4 2017 and held it in 1 quarter.
Wedbush Securities's Carisma Therapeutics position peaked at $13K in Q4 2017.
27 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2018.

Based on Wedbush Securities's 13F filing for Q1 2018, filed 1 May 2018.